Gilead Sciences Inc. struggles as market pressures mount.
Gilead Sciences Inc. (NASDAQ:GILD) saw its stock price drop by 2.00% in today's trading session, closing at CA$149.17. This decline comes amid concerns about the company's financial health and ongoing challenges in its product portfolio.
Investor takeaway: Investors should be cautious as Gilead faces significant headwinds, including substantial losses and declining cash reserves, which could impact future growth.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$187.15B
Div. yield
2.15%
Div. / share
$3.22
52W high
$154.51
52W low
$105.84
1W change
+1.10%
Beta
0.35
Analyst Price Targets
Based on 30 analysts covering GILD · as of Sep 24, 2026
Wall Street analysts forecast GILD stock price to rise 417.5% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
C$158.65
+417.5% Upside
Previously C$158.15 on Sep 17, 2026
Current Price
C$30.66
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
24.0%
Annualized
90-Day Vol
27.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$181.97
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$161.55 | C$148.73 – C$175.47 |
| 60 trading days | C$171.45 | C$152.54 – C$192.71 |
| 90 trading days | C$181.97 | C$157.70 – C$209.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Gilead's stock down 2.00% amid financial concerns
The company's market cap stands at approximately $188.73 billion, but its profit margin remains negative at -10.64%, highlighting ongoing profitability challenges.
Bull case
Gilead's HIV franchise continues to show strong sales growth, especially for its leading products like Biktarvy and Descovy. This growth could help stabilize revenue in the long run.
Bear case
The company reported a significant GAAP diluted loss per share of $(8.45) due to high acquisition costs and declining sales in non-HIV segments. This raises concerns about its financial stability.
Advertisement
Financial Performance Under Scrutiny
Gilead's recent financial performance has raised eyebrows, with a reported GAAP diluted loss per share of $(8.45) for Q2 2026. This loss was primarily due to $11.2 billion in acquired in-process R&D charges, which have significantly impacted the company's cash reserves. From a high of $10.6 billion at the end of 2025, Gilead's cash and equivalents have dwindled to just $3.2 billion, raising concerns about its ability to sustain operations and fund future growth initiatives.
Challenges Beyond HIV
While Gilead's HIV product sales have shown resilience, with a 12% year-over-year increase, other segments are struggling. Sales from its oncology products, such as Cell Therapy, fell by 14%, and the company faces intense competition in these areas. The reliance on its HIV portfolio for revenue stability highlights the vulnerability of Gilead's broader business strategy, as it seeks to diversify its offerings amid declining performance in legacy products.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
